Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy
ACS Pharmacology & Translational Science · 2024-05-10 · 7 (5) · 1395-1403
DOI: 10.1021/acsptsci.4c00035 ↗At a glance
Journal article in ACS Pharmacology & Translational Science, published online on 2024-04-29. Written by Ryotaro Onoue and 2 co-authors. Institution: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan. Cited 5 times so far (Crossref); 35 references. The full text is freely available in PubMed Central. Funded by: Fusion Oriented REsearch for disruptive Science and Technology.
Abstract (original language)
Auger electron therapy and photodynamic therapy (PDT) have attracted attention as powerful anticancer modalities. Herein, we report the development of novel bimodal agents for Auger electron therapy and PDT, and their application to combination therapy. [125I]NBH-1/NBH-1 and [125I]NBH-2/NBH-2, composing Hoechst and iodostyryl-BODIPY, were synthesized and evaluated regarding their usefulness as bimodal agents. [125I]NBH-1 showed significantly higher nuclear uptake than [125I]NBH-2 and radioactivity-dependent cytotoxicity induced by Auger electrons. In addition, NBH-1 exhibited photoinduced cytotoxicity. Combination therapy using [125I]NBH-1 and NBH-1 with light irradiation induced a superior cytotoxicity to these treatments alone. In tumor-bearing mice injected with NBH-1 or [125I]NBH-1/NBH-1 under light irradiation, significant tumor growth inhibition was observed compared with that of the control group. Especially, [125I]NBH-1/NBH-1 under light irradiation showed the strongest therapeutic effects among all treatments. These results suggest that [125I]NBH-1/NBH-1 is a potent bimodal agent for Auger therapy and PDT and that combination therapy using [125I]NBH-1 and NBH-1 shows enhanced therapeutic efficacy.
Authors and institutions
- Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
ORCID profiles: Hiroyuki Watanabe, Masahiro Ono
Funding
- Fusion Oriented REsearch for disruptive Science and Technology
Cite
APA
Onoue, R., Watanabe, H., & Ono, M. (2024). Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy. ACS Pharmacology & Translational Science, 7(5), 1395-1403. https://doi.org/10.1021/acsptsci.4c00035
Vancouver
Onoue R, Watanabe H, Ono M. Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy. ACS Pharmacology & Translational Science. 2024;7(5):1395-1403. doi:10.1021/acsptsci.4c00035
BibTeX
@article{Onoue2024,
author = {Onoue, Ryotaro and Watanabe, Hiroyuki and Ono, Masahiro},
title = {Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy},
journal = {ACS Pharmacology & Translational Science},
year = {2024},
volume = {7},
number = {5},
pages = {1395--1403},
doi = {10.1021/acsptsci.4c00035}
}
EUVIMED